NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE Drug Patent Profile

« Back to Dashboard

When do Norethindrone Acetate And Ethinyl Estradiol And Ethinyl Estradiol And Ferrous Fumarate patents expire, and when can generic versions of Norethindrone Acetate And Ethinyl Estradiol And Ethinyl Estradiol And Ferrous Fumarate launch?

Norethindrone Acetate And Ethinyl Estradiol And Ethinyl Estradiol And Ferrous Fumarate is a drug marketed by Xiromed and is included in one NDA.

The generic ingredient in NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE is ethinyl estradiol; norethindrone acetate. There is one drug master file entry for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Summary for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE at DailyMed

US Patents and Regulatory Information for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xiromed	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	205049-001	May 31, 2016		DISCN	No	No

Norethindrone Acetate and Ethinyl Estradiol With Ferrous Fumarate: Market Dynamics, Patent Status and Financial Trajectory

Last updated: August 2, 2026

Norethindrone acetate, ethinyl estradiol, ethinyl estradiol and ferrous fumarate is a mature combined oral contraceptive formulation associated with Loestrin 24 Fe and generic equivalents. Its commercial profile has shifted from branded specialty contraception to a price-driven generic market. Patent barriers have largely ceased to control access, while manufacturer competition, pharmacy substitution, payer formularies and product availability now determine market share.

The formulation generally contains 24 tablets with norethindrone acetate 1 mg and ethinyl estradiol 20 mcg, followed by low-dose ethinyl estradiol tablets and ferrous fumarate tablets. The exact tablet sequence varies by product and labeling.

What is the formulation and how is it used?

The product is an oral hormonal contraceptive combining a progestin, an estrogen and iron-containing reminder tablets.

Component	Typical role
Norethindrone acetate	Progestin that suppresses ovulation and thickens cervical mucus
Ethinyl estradiol	Estrogen that stabilizes the endometrium and supports ovulation suppression
Ferrous fumarate	Iron-containing reminder tablet with no contraceptive activity
Low-dose ethinyl estradiol tablets	Provides estrogen during part of the hormone-free interval in certain 28-day regimens

Loestrin 24 Fe was the principal reference brand associated with the formulation. Generic products are usually marketed under the active-ingredient name rather than under a consumer brand.

The product is indicated for pregnancy prevention. Like other estrogen-containing contraceptives, its labeling includes warnings concerning thromboembolic events, cardiovascular risk, smoking, hypertension, migraine, liver disease and other contraindications. The safety profile limits expansion into older or higher-risk populations.

What brands and generic products compete with this formulation?

The market includes direct generics, related norethindrone acetate and ethinyl estradiol products, and newer branded contraceptives with similar hormone content.

Product category	Representative product	Competitive relationship
Reference product	Loestrin 24 Fe	Historical reference brand
Direct generic	Norethindrone acetate and ethinyl estradiol, with ethinyl estradiol and ferrous fumarate	Therapeutically equivalent or closely equivalent generic version, depending on product labeling
Related branded product	Minastrin 24 Fe	Similar hormone combination but different dosage form and regimen
Related branded product	Taytulla	Capsule formulation containing norethindrone acetate and ethinyl estradiol with ferrous fumarate reminder capsules
Other oral contraceptives	Microgestin, Junel, Blisovi and other norethindrone-containing products	Compete within the same contraceptive class but may use different dosing schedules

Minastrin 24 Fe and Taytulla are not interchangeable with every Loestrin 24 Fe generic. Their dosage forms, inactive ingredients, tablet or capsule design and regulatory product codes can differ.

The closest commercial substitutes are other low-dose combined oral contraceptives. Prescribers and pharmacies commonly move between products when formulary status, copayment, supply or patient tolerance changes.

When did the product lose branded exclusivity?

The product lost meaningful commercial exclusivity when generic manufacturers entered the U.S. market. Loestrin 24 Fe was exposed to generic competition after patent litigation and settlement activity involving Warner Chilcott and prospective generic manufacturers.

The relevant commercial sequence was:

Period	Market event
Pre-generic period	Warner Chilcott marketed Loestrin 24 Fe as a branded oral contraceptive
Patent challenge period	Generic manufacturers filed abbreviated new drug applications and raised patent challenges
2010s	Generic versions entered or prepared to enter the market following litigation and settlement activity
Post-entry period	Pharmacy substitution and payer preference shifted volume toward lower-priced products
Current mature-market period	The formulation competes primarily on price, availability, supplier reliability and formulary placement

A precise single loss-of-exclusivity date is difficult to apply because commercial entry depended on separate generic approvals, patent positions, settlements and product-specific regulatory status. The principal economic event was generic entry during the 2010s, not a future patent cliff.

What patents protected Loestrin 24 Fe?

The Loestrin 24 Fe patent estate included formulation and dosing claims relating to the combination of norethindrone acetate and ethinyl estradiol and the use of low-dose estrogen tablets during the latter portion of the regimen. The estate was litigated against generic applicants.

The key legal issue was not simply whether the active ingredients were old. The commercial dispute focused on whether the particular regimen, tablet sequence, formulation and related claims could delay or restrict generic entry.

The First Circuit reviewed antitrust claims involving patent settlements in In re Loestrin 24 Fe Antitrust Litigation, 814 F.3d 538 (1st Cir. 2016). The case concerned allegations surrounding settlements between the brand company and generic manufacturers. The decision is relevant to the broader legal treatment of reverse-payment arrangements in pharmaceutical patent litigation.

Patent protection for the product is now commercially weak because:

1. The active ingredients are long-established.
2. The product is a conventional oral solid dosage form.
3. The principal formulation concepts have been publicly disclosed and challenged.
4. Multiple generic manufacturers have entered the market.
5. No biologic manufacturing process or complex delivery system creates a durable technical barrier.

The remaining risk is product-specific rather than franchise-wide. A manufacturer may still hold patents on a particular improved formulation, chewable dosage form, packaging configuration or manufacturing process, but those rights do not recreate the original Loestrin 24 Fe monopoly.

What is the Orange Book status of norethindrone acetate and ethinyl estradiol with ferrous fumarate?

The FDA Orange Book is the primary source for identifying reference-listed drugs, therapeutic-equivalence evaluations and listed patents for approved small-molecule products. The relevant products are approved through the abbreviated new drug application pathway when a generic applicant demonstrates bioequivalence to the reference product.

For this formulation, the commercial significance of Orange Book status is limited compared with an active, high-value patent estate. The reference product and generic products are governed by product-specific application numbers, labeling and therapeutic-equivalence codes.

Regulatory issue	Commercial effect
Reference-listed drug status	Establishes the product used for generic comparison
ANDA approval	Allows generic marketing after FDA approval and satisfaction of patent certifications
Therapeutic-equivalence rating	Supports pharmacy substitution where state law and payer rules permit
Listed patents	Can trigger Paragraph IV litigation or delayed approval
Regulatory exclusivity	No meaningful current exclusivity period is expected to protect the mature formulation

The FDA does not treat this product as a biologic. Biosimilar approval under the Public Health Service Act is therefore irrelevant. Competition occurs through generic drug approvals under the Federal Food, Drug, and Cosmetic Act.

How did Paragraph IV challenges affect the market?

Generic applicants typically use Paragraph IV certifications when they assert that listed patents are invalid, unenforceable or not infringed. A Paragraph IV notice can trigger patent litigation under the Hatch-Waxman framework and may create a 30-month stay of FDA approval in qualifying circumstances.

The Loestrin 24 Fe disputes illustrate the financial importance of patent settlement terms. A settlement can:

• Delay generic launch.
• Permit an earlier authorized or licensed generic.
• Establish a negotiated entry date.
• Allocate commercial rights between the brand company and generic applicant.
• Affect whether competing applicants can enter before or after the first challenger.

In a mature contraceptive market, a delayed generic launch can preserve significant brand revenue because prescriptions are highly substitutable and price-sensitive. Once multiple generics enter, the value of the original patent dispute declines rapidly.

How strong is the patent estate?

The patent estate is commercially weak today.

Patent-strength factor	Assessment
Active ingredient novelty	Low
Dosage-form complexity	Low to moderate
Formulation differentiation	Moderate historically, low after generic entry
Manufacturing barriers	Low
Regulatory switching costs	Low to moderate
Litigation leverage	Historically material, currently limited
Biosimilar protection	Not applicable
Geographic exclusivity	Primarily jurisdiction-specific and largely exhausted in the U.S.

The formulation does not require a complex device, sterile manufacturing process, specialized cold chain or biologic cell line. Generic manufacturers can generally source the active ingredients and produce conventional oral tablets through established facilities.

What is the financial trajectory for the product?

The financial trajectory follows the standard branded-to-generic pattern.

Branded growth phase

Before generic competition, Loestrin 24 Fe benefited from:

• A recognized contraceptive brand.
• Prescriber familiarity.
• A differentiated 24-day active-tablet regimen.
• Potentially higher reimbursement than generic alternatives.
• Revenue from a broader Loestrin franchise.

The commercial value was concentrated in the reference brand and the company’s ability to maintain formulary access.

Patent-challenge and settlement phase

During litigation, revenue depended on the timing of generic approval and launch. Patent settlements could extend branded cash flows but also create future competitive certainty. The economic value of the estate was highest during the period when a first generic launch could be delayed.

Generic erosion phase

After generic entry, revenue typically declines through three mechanisms:

1. Lower net pricing.
2. Pharmacy substitution away from the brand.
3. Expansion of generic supplier capacity.

A brand may retain residual revenue through patient loyalty, physician preference, coupons, Medicaid rules or supply disruptions affecting generics. Those factors rarely restore the original margin structure.

Mature generic phase

The current market is primarily a volume and supply-chain business. Revenue depends on:

• Contract awards from wholesalers and pharmacy benefit managers.
• Product availability.
• Manufacturing cost.
• Active pharmaceutical ingredient sourcing.
• Recall history and quality performance.
• The number of approved suppliers.
• State substitution rules.
• Reimbursement spreads.

Product-level revenue is generally not disclosed separately by generic manufacturers. Public company filings usually aggregate oral contraceptive revenue within broader women’s health, generic pharmaceutical or U.S. pharmaceutical segments. As a result, direct revenue estimates for this exact active-ingredient combination are less reliable than company-wide generic revenue figures.

Which companies are most exposed to the formulation?

The original brand exposure was associated with Warner Chilcott, later integrated into Actavis and then Allergan following corporate transactions. Generic exposure is distributed across companies with approved or marketed products, including large U.S. and international generic manufacturers.

The relevant economic exposure differs by company:

Company type	Exposure
Original brand owner	Historical revenue loss and residual brand sales
Generic manufacturer	Low-margin prescription volume
Contract manufacturer	Production revenue without direct pricing control
Wholesaler	Distribution volume and inventory turnover
Pharmacy benefit manager	Formulary and rebate economics
Retail pharmacy	Dispensing volume and substitution economics

No single generic supplier necessarily controls the category. Generic contraceptives often experience periodic supply concentration when manufacturers discontinue low-margin products or face manufacturing constraints.

What generic launch scenarios exist?

Three scenarios define the market.

Base case: stable generic competition

Multiple suppliers remain active, pricing stays compressed and the brand retains only a small residual share. This is the most likely mature-market outcome.

Consolidation scenario

One or more suppliers exit because of low margins, manufacturing problems or limited contracting value. Remaining suppliers gain volume and may experience modest pricing improvement. Shortages become more likely if manufacturing capacity is concentrated.

Supply-disruption scenario

A plant issue, quality action or API constraint reduces available supply. Pharmacies may temporarily substitute among norethindrone-containing oral contraceptives. Any resulting revenue benefit for another supplier is usually temporary.

A return to premium branded pricing is unlikely without a new delivery system, clinically differentiated regimen or strong patient adherence advantage.

What geographic markets matter?

The United States is the most important market for Orange Book and Paragraph IV analysis. Patent rights and regulatory approvals are territorial, so U.S. loss of exclusivity does not determine European, Canadian, Latin American or Asian market outcomes.

Outside the U.S., competition is shaped by:

• National marketing authorizations.
• Reference-pricing systems.
• Public procurement.
• Local substitution rules.
• National patent terms.
• Brand-prescribing practices.
• Local manufacturing requirements.

The active ingredients are widely known internationally, which limits the likelihood of durable geographic exclusivity based solely on the molecule combination.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are limited but operationally important. The product requires validated production of low-dose hormone tablets, consistent content uniformity, dissolution control, packaging and regulatory compliance. Low-dose hormonal products can require careful analytical testing because small deviations may affect product quality.

The principal barriers are therefore execution-based:

• Reliable API supply.
• FDA-compliant manufacturing.
• Batch release testing.
• Stable packaging.
• Pharmacovigilance.
• Retail and wholesaler contracts.

These barriers can affect market share without creating patent exclusivity.

Key Takeaways

• The formulation is a mature combined oral contraceptive associated with Loestrin 24 Fe and generic equivalents.
• Its commercial exclusivity was eroded by generic entry during the 2010s.
• Patent litigation and Paragraph IV challenges were important historically but no longer provide a meaningful franchise-wide barrier.
• The product is regulated as a conventional small-molecule drug, not a biologic, so biosimilar competition is irrelevant.
• Current market share depends on price, formulary access, supply reliability and pharmacy substitution.
• Financial exposure is concentrated in generic volume and manufacturing efficiency rather than premium brand pricing.
• Product-level revenue is generally not separately disclosed by generic manufacturers.
• The principal future risks are supplier exit, manufacturing disruption, recalls and reimbursement compression.

FAQs About Norethindrone Acetate, Ethinyl Estradiol and Ferrous Fumarate

Is Loestrin 24 Fe still patent protected?

The commercially meaningful patent protection associated with Loestrin 24 Fe has been overtaken by generic entry. Historical patents and litigation remain relevant for legal analysis, but they do not prevent broad generic competition.

Is norethindrone acetate and ethinyl estradiol with ferrous fumarate a generic drug?

Yes. Products using this active-ingredient description are generally generic versions or related versions of branded low-dose oral contraceptives. The exact dosage schedule and therapeutic-equivalence status depend on the FDA-approved product.

Can pharmacies substitute this product for Taytulla?

Not automatically. Taytulla is a different dosage form and may have different product-specific labeling and therapeutic-equivalence status. Substitution depends on the prescription, FDA equivalence designation and applicable state law.

Does ferrous fumarate provide contraceptive protection?

No. Ferrous fumarate tablets are reminder tablets and do not provide hormonal contraception. Contraceptive protection comes from the active hormone tablets taken according to the approved regimen.

What is the main investment risk in this market?

The main risk is margin compression caused by generic competition. Secondary risks include manufacturing disruption, supplier consolidation, regulatory quality actions and loss of pharmacy benefit manager contracts.

References

1. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2024). DailyMed: Norethindrone acetate and ethinyl estradiol tablets and ethinyl estradiol tablets. National Library of Medicine.

4. In re Loestrin 24 Fe Antitrust Litigation, 814 F.3d 538 (1st Cir. 2016).

5. Warner Chilcott Company, LLC. (2012). Annual report and public company filings concerning the Loestrin franchise. U.S. Securities and Exchange Commission.